8.2503

0.52% 0.0403

Theravance Biopharma Inc (TBPH)

Overview News Price History Option Chain Financials Discussions Forecast

Theravance Biopharma Inc stock is traded at $8.2503, with a volume of 30,806. It is up +0.52% in the last 24 hours and up +1.89% over the past month. Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Previous Close:

$8.21

Open:

$8.26

24h Volume:

30,806

Relative Volume:

0.11

Market Cap:

$398.31M

Revenue:

$62.02M

Net Income/Loss:

$-45.65M

P/E Ratio:

0.7263

EPS:

11.36

Net Cash Flow:

$-9.60M

1W Performance:

-4.59%

1M Performance:

+1.89%

6M Performance:

-12.76%

1Y Performance:

-16.21%

1-Day Range:

$8.139

$8.27

1-Week Range:

$8.139

$8.65

52-Week Range:

$7.44

$11.71

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name

Theravance Biopharma Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

650-808-6000

Address

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TBPH's Discussions on Twitter

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-23-22	Initiated	SVB Leerink	Outperform
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-07-20	Initiated	JP Morgan	Overweight
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight
May-13-20	Initiated	Cowen	Outperform
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral
Oct-29-19	Initiated	H.C. Wainwright	Buy
Mar-29-18	Resumed	Piper Jaffray	Overweight
Aug-17-17	Initiated	Evercore ISI	Outperform
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
May-11-17	Reiterated	Needham	Buy
Dec-21-16	Initiated	Needham	Buy
Nov-03-16	Initiated	Piper Jaffray	Overweight
Oct-12-16	Downgrade	Robert W. Baird	Neutral → Underperform
Aug-03-16	Downgrade	BofA/Merrill	Neutral → Underperform
Jun-20-16	Initiated	Guggenheim	Buy
Jun-20-16	Reiterated	Leerink Partners	Outperform
May-12-16	Initiated	Leerink Partners	Outperform
May-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Feb-03-15	Upgrade	Robert W. Baird	Underperform → Neutral

View All

Theravance Biopharma Inc Stock (TBPH) Latest News

10:37 AM

Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - MarketBeat

10:37 AM

03:51 AM

Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com

03:51 AM

Nov 04, 2024

(TBPH) Proactive Strategies - Stock Traders Daily

Nov 04, 2024

Oct 26, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat

Oct 26, 2024

Oct 24, 2024

When (TBPH) Moves Investors should Listen - Stock Traders Daily

Oct 24, 2024

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan

Oct 24, 2024

Oct 23, 2024

Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat

Oct 23, 2024

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World

Oct 23, 2024

Oct 22, 2024

What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat

Oct 22, 2024

Oct 20, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts - MarketBeat

Oct 20, 2024

The Manufacturers Life Insurance Company Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Oct 20, 2024

Oct 19, 2024

Theravance study shows YUPELRI improves COPD lung function By Investing.com - Investing.com Australia

Oct 19, 2024

Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat

Oct 19, 2024

Oct 18, 2024

Theravance study shows YUPELRI improves COPD lung function - Investing.com

Oct 18, 2024

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - StockTitan

Oct 18, 2024

Oct 14, 2024

Where are the Opportunities in (TBPH) - Stock Traders Daily

Oct 14, 2024

Oct 11, 2024

Dimensional Fund Advisors LP Has $2.80 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Oct 11, 2024

Oct 10, 2024

Theravance Biopharma (STU:0TB) Price-to-Operating-Cash-Flow : (As of Oct. 10, 2024) - GuruFocus.com

Oct 10, 2024

Oct 07, 2024

Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Oct 07, 2024

Oct 06, 2024

Bank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Oct 06, 2024

Oct 04, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat

Oct 04, 2024

Oct 03, 2024

(TBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 03, 2024

Oct 02, 2024

XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Oct 02, 2024

Sep 28, 2024

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN

Sep 28, 2024

Sep 25, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Sep 25, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Sep 25, 2024

Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Sep 25, 2024

Sep 23, 2024

An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily

Sep 23, 2024

Theravance Biopharma settles patent litigation with Qilu Pharmaceutical - Investing.com

Sep 23, 2024

Sep 21, 2024

Baupost Group LLC MA Decreases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Sep 21, 2024

Sep 17, 2024

Theravance Biopharma (NASDAQ:TBPH) Given “Buy” Rating at HC Wainwright - Defense World

Sep 17, 2024

Sep 16, 2024

H.C. Wainwright maintains Buy rating on Theravance Biopharma shares By Investing.com - Investing.com Canada

Sep 16, 2024

Theravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from HC Wainwright - MarketBeat

Sep 16, 2024

Unveiling 4 Analyst Insights On Theravance Biopharma - Benzinga

Sep 16, 2024

Sep 11, 2024

How To Trade (TBPH) - Stock Traders Daily

Sep 11, 2024

Leerink Partners gives a Market perform recommendation for Theravance Biopharma Inc (TBPH) - Knox Daily

Sep 11, 2024

Sep 10, 2024

Seth Klarman's Complete Exit from Theravance Biopharma Inc - Yahoo Finance

Sep 10, 2024

Theravance Biopharma Outlines Growth Strategy at Investment Conference - TipRanks

Sep 10, 2024

Sep 06, 2024

Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance

Sep 06, 2024

Sep 04, 2024

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 04, 2024

Sep 02, 2024